What Key Medical Contraindications And Clinical History Factors Must Be Evaluated Prior To Performing Er:yag Laser Skin Resurfacing? Ensure Safe Outcomes With Thorough Screening

Before Er:YAG laser skin resurfacing, clinicians must screen for factors that impair wound healing, increase scarring or pigmentary complications, or make treatment unsafe. Key concerns include active infection or suspicious lesions, recent oral isotretinoin use, keloid or hypertrophic-scar tendency, impaired immunity, damaged adnexal structures, significant dermal thinning or fibrosis, eyelid laxity, darker phototype, and unrealistic expectations. The final decision should also account for the planned treatment depth, field size, and whether the procedure is full-field or fractional.

The central safety question is whether the patient can re-epithelialize predictably and tolerate the expected risks. Patients with active disease, impaired healing capacity, high scarring risk, or unrealistic expectations may require postponement, modified parameters, alternative treatment, or exclusion from ablative resurfacing.

Screen for Conditions That Directly Prevent Safe Resurfacing

Active infection or inflammation

Treatment should be deferred in areas with active bacterial, viral, or fungal infection. Particular attention is required for active or recurrent herpes simplex, especially when treating the perioral region.

Active inflammatory or koebnerizing disorders, such as labile psoriasis or vitiligo, also require careful assessment because injury may worsen or extend the disease.

Suspicious lesions or active skin cancer

The treatment field should be examined for uncharacterized, suspicious, or actively malignant lesions. These should be diagnosed and managed before cosmetic resurfacing rather than ablated without a clear diagnosis.

Impaired immune function

Review conditions and medications that compromise immunity. Immunosuppression can increase the risk of infection, delay healing, and produce less predictable outcomes.

Pregnancy and other elective-procedure considerations

Pregnancy should generally be treated as a reason to defer elective ablative resurfacing. The clinician should also identify any acute systemic illness or medical instability that could make wound care or infection management unsafe.

Review Medication and Treatment History

Recent oral isotretinoin use

Recent systemic isotretinoin is a major contraindication or postponement factor because it may impair epithelial recovery and increase the risk of abnormal scarring.

The primary reference identifies use within the previous six months as an absolute contraindication. Other protocols use six to twelve months, and some recommend longer intervals for deep full-field treatment; therefore, the clinician should follow the device-specific protocol and local standards, using a conservative interval when treatment is extensive or deep.

Other agents that may thin or alter the dermis

Ask about prolonged use of topical retinoids, glycolic acid, and related exfoliating or dermis-altering products. These may increase fragility and should prompt an assessment of skin thickness, irritation, and recovery capacity.

The patient should also disclose recent deep chemical peels, dermabrasion, prior laser resurfacing, extensive electrolysis, or other procedures that may have damaged appendages or altered the dermis.

Medications affecting healing or infection risk

A complete medication history should identify immunosuppressive therapy, drugs affecting hemostasis, and medications that could complicate anesthesia, wound care, or infection treatment. These are not automatically prohibitive in every case, but they may require medical coordination or protocol modification.

Assess Whether the Skin Can Re-Epithelialize Normally

Compromised adnexal structures

Hair follicles and sebaceous glands provide important epithelial progenitor cells for resurfacing recovery. Treatment is higher risk when these structures are reduced or absent because of:

Scleroderma or substantial dermal sclerosis
Prior deep burns or burn scars
Previous ionizing radiation
Deep prior peels, dermabrasion, or laser procedures
Extensive follicular destruction

Irradiated or heavily scarred skin may heal slowly or unpredictably and may be unsuitable for deep full-field ablation.

Existing dermal fibrosis

Prior aesthetic procedures can create dermal fibrosis, which may reduce treatment uniformity and increase the risk of abnormal texture, delayed healing, or an unpredictable response. The clinician should determine what procedures were performed, when they occurred, and whether the treatment field contains significant scar tissue.

Vascular and connective-tissue disease

Ask about scleroderma, lupus, Sjögren syndrome, other collagen vascular diseases, and significant vascular compromise. These conditions may reduce tissue perfusion or make wound healing less predictable.

Active disease, severe involvement of the treatment area, or prior radiation may warrant avoiding deep ablative treatment or obtaining specialist input.

Smoking and vascular risk

Active smoking can impair tissue oxygenation and healing. It should be specifically documented during the history, particularly when treating large areas or performing deeper full-field resurfacing.

Evaluate Scarring and Pigmentary Risk

Keloid or hypertrophic-scar tendency

A personal history of keloids or hypertrophic scars, especially in the proposed treatment area, is a major warning sign. The clinician should ask about scars after surgery, acne, trauma, piercings, burns, and previous laser treatments.

The primary reference treats an active tendency toward keloid or hypertrophic-scar formation as an absolute contraindication. In less severe or remote histories, some practitioners may consider conservative settings or a test spot, but the risk cannot be eliminated.

Fitzpatrick skin type

Document the patient’s Fitzpatrick skin phototype and history of post-inflammatory hyperpigmentation or hypopigmentation. Darker phototypes, particularly IV–VI, have a higher risk of persistent pigmentary change after deep or regional ablative treatment.

This does not necessarily prohibit every Er:YAG procedure. It may favor superficial or fractional treatment, conservative parameters, strict photoprotection, and a clear discussion of pigmentary risk.

Prior abnormal pigmentation

Ask specifically about:

Previous post-inflammatory hyperpigmentation
Persistent hypopigmentation
Melasma, particularly if active
Dyspigmentation after acne, surgery, or cosmetic procedures
Poor response to prior laser or peel treatments

Active melasma is a reason to defer or reconsider resurfacing because inflammation may worsen pigmentation.

Examine the Eyelids for Mechanical Risk

Lower-eyelid laxity

Periorbital resurfacing can contract the skin and increase the risk of ectropion, especially when lower-eyelid support is poor. Examine for lower-eyelid laxity, snap-back, scleral show, and other signs of inadequate lid support.

Prior eyelid surgery

A history of blepharoplasty or other periocular surgery can reduce tissue reserve or alter eyelid mechanics. Significant laxity or previous surgery may require modified treatment, additional precautions, or avoidance of aggressive periorbital ablation.

Confirm Expectations and Ability to Follow Care

Unrealistic expectations

A patient who expects flawless skin, no downtime, or complete removal of wrinkles and scars is not an appropriate candidate until expectations are corrected. Resurfacing can improve texture, dyschromia, rhytids, and selected scars, but it cannot guarantee a specific cosmetic result.

Compliance with aftercare

Assess whether the patient can reliably follow wound-care instructions, avoid sun exposure, use prescribed medications, attend follow-up visits, and report infection or delayed healing.

Poor compliance is a contraindication because postoperative care is part of the treatment itself. Inadequate wound care can convert a technically appropriate procedure into an avoidable complication.

Understanding the Trade-offs

Absolute versus relative contraindications

The distinction depends on treatment depth and technique. A factor that may prohibit deep, full-field ablation may not necessarily prohibit a superficial or fractional procedure.

However, this distinction should not be used to minimize serious risks. Active infection, impaired healing, recent systemic isotretinoin exposure, severe adnexal loss, and unrealistic expectations generally require postponement or exclusion rather than simply lowering the energy.

Conservative treatment reduces risk but not to zero

Lower fluence, reduced density, test spots, smaller treatment areas, and fractional delivery may reduce complications in selected higher-risk patients. They do not fully eliminate the risks of scarring, infection, pigmentary change, or delayed healing.

Darker skin requires more than parameter adjustment

Er:YAG’s more superficial and controllable ablation profile may help limit thermal injury, but skin phototype remains clinically important. Patients with darker skin or a strong PIH history need explicit counseling and may be better served by less aggressive treatment or a nonablative alternative.

Making the Right Choice for Your Goal

The screening process should match the patient’s risk profile to the intended depth and treatment area.

If your primary focus is wound-healing safety: Defer treatment for active infection, recent systemic isotretinoin exposure, major immune compromise, severely damaged adnexal skin, or significant vascular/connective-tissue disease.
If your primary focus is minimizing scarring: Exclude or use extreme caution in patients with keloid or hypertrophic-scar tendencies, dermal fibrosis, deep prior procedures, or unrealistic expectations.
If your primary focus is preventing pigmentary complications: Document Fitzpatrick type and prior PIH, reconsider deep treatment in darker phototypes, and address active melasma before resurfacing.
If your primary focus is periorbital treatment: Evaluate lower-eyelid laxity and prior blepharoplasty because contraction can cause postoperative ectropion.
If your primary focus is treatment success: Confirm that the patient understands downtime and can comply fully with wound care, antiviral precautions when indicated, photoprotection, and follow-up.

Safe Er:YAG resurfacing begins with selecting a patient whose skin, medical history, expectations, and aftercare capacity support predictable healing.

Summary Table:

Factor	Key Considerations
Active infection/inflammation	Defer treatment; treat herpes simplex prophylactically
Recent oral isotretinoin	Wait 6-12 months; absolute contraindication per some protocols
Keloid/scar tendency	High risk of abnormal scarring; avoid or extreme caution
Immunosuppression/medications	Increased infection risk; coordinate with physician
Adnexal damage (scleroderma, burns)	Poor re-epithelialization; avoid deep ablation
Fitzpatrick IV-VI / PIH history	Higher pigment risk; consider superficial/fractional
Eyelid laxity/prior surgery	Risk of ectropion; modify or avoid periorbital treatment
Unrealistic expectations	Correct expectations; ensure compliance
Pregnancy/acute illness	Defer elective procedure

At BELIS, we prioritize patient safety in aesthetic medicine. Our advanced Er:YAG and other laser systems are designed for precision and control, but optimal outcomes start with rigorous patient selection. Partner with us to access cutting-edge technology, comprehensive training, and expert support. Contact us today to learn how we can help you deliver safe, effective treatments and grow your practice.